Skip to main content

Table 1 MMP-11 Levels and Clinical Characteristics

From: Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

Clinical data No. of Case (%) MMP-11 level P -value
   Mean ± SD (ng/ml)  
NO. of patients 86   
Gender    
Male 60(69.8%) 45.76 ± 22.89 0.200
Female 26(30.2%) 38.79 ± 23.17  
Age (yrs)    
Median 51(50-56)   
<65 63(73.3%) 43.40 ± 22.76 0.166
≥65 23(26.7%) 50.79 ± 21.96  
Differentiation    
G1, G2 23(26.7%) 48.56 ± 23.30 0.235
G3 63(73.3%) 41.86 ± 22.90  
Histology    
Intestinal type adenocarcinoma 54(62.8%) 44.22 ± 23.92  
Mucinous carcinoma 20(23.2%) 45.89 ± 17.99 0.527
Signet-ring cell carcinoma 12(14.0%) 53.44 ± 23.80  
ECOG    
0-1 68(79.1%) 46.14 ± 21.40 0.610
2 18(20.9%) 43.33 ± 26.49  
Disease stage    
III c 26(30.2%) 43.22 ± 31.02 0.288
IV 60(69.8%) 48.45 ± 23.57  
Metastasis site    
Lymph node 35(40.7%) *# 52.55 ± 24.72  
Peritoneum 21(24.4%) # 33.44 ± 14.46 0.006 (*0.029, #0.002)
Internal organs 30(34.9%) * 40.42 ± 22.74  
Chemotherapy cycles 377   
Median 6.00(3.00-12.00)   
mTTP (m)    
Median 6.00(5.29-6.71)   
mOS (m)    
Median 10.00(8.51-11.50)   
Response    
PR 38(44.2% ) 46.85 ± 24.92 0.182
SD 22(25.6% ) 37.34 ± 19.95  
PD 26(30.2% ) 48.97 ± 20.23  
  1. Abbreviations: PR, partial response; SD, stable disease; PD, progression of disease. Analysis of the difference between groups using analysis of variance (ANOVA). Where differences were identified, further analysis (between pairs of groups, with respective pairs for each molecule marked with *and *) was performed using Scheffe (95% confidence interval (CI))